Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Quimioteràpia combinada"'
Autor:
Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja J. A. de Jonge, Jean-Yves Blay, Antoine Italiano, Kan Yonemori, Daniel C. Cho, Filip Y. F. L. de Vos, Philippe Moreau, Elena Elez Fernandez, Jan H. M. Schellens, Christoph C. Zielinski, Suman Redhu, Aislyn Boran, Vanessa Q. Passos, Palanichamy Ilankumaran, Yung-Jue Bang
Publikováno v:
Nature medicine, vol 29, iss 5
Scientia
Nature Medicine, 29(5), 1103-1112. Nature Publishing Group
Scientia
Nature Medicine, 29(5), 1103-1112. Nature Publishing Group
BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor) in eight cohorts of patients with BRAFV600E-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c4ebaa45d1da62d0ac5f9e5a60659de
http://www.scopus.com/inward/record.url?scp=85152683237&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85152683237&partnerID=8YFLogxK
Autor:
Luis G. Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, Jaafar Bennouna, Michael Schenker, Ying Cheng, Oscar Juan-Vidal, Hideaki Mizutani, Alejo Lingua, Felipe Reyes-Cosmelli, Niels Reinmuth, Juliana Menezes, Jacek Jassem, Svetlana Protsenko, Eduardo Richardet, Enriqueta Felip, Kynan Feeney, Bogdan Zurawski, Aurelia Alexandru, Emmanuel de la Mora Jimenez, Shaker Dakhil, Shun Lu, Martin Reck, Thomas John, Nan Hu, Xiaoqing Zhang, Judi Sylvester, Laura J. Eccles, Diederik J. Grootendorst, David Balli, Jaclyn Neely, David P. Carbone
Publikováno v:
Scientia
Non–small cell lung cancer; Brain metastases; Somatic mutations Càncer de pulmó de cèl·lules no petites; Metàstasis cerebrals; Mutacions somàtiques Cáncer de pulmón de células no pequeñas; Metástasis cerebrales; Mutaciones somáticas Int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1273c44ad3440298c0d6bb6ae78e198
https://doi.org/10.1016/j.jtho.2022.10.014
https://doi.org/10.1016/j.jtho.2022.10.014
Autor:
Ana Oaknin, Bradley J. Monk, Ignace Vergote, Andreia Cristina de Melo, Yong-Man Kim, Alla S. Lisyanskaya, Vanessa Samouëlian, Hee Seung Kim, Evgeniy A. Gotovkin, Fernanda Damian, Chih-Long Chang, Shunji Takahashi, Jingjin Li, Melissa Mathias, Matthew G. Fury, Cristina Ivanescu, Matthew Reaney, Patrick R. LaFontaine, Israel Lowy, James Harnett, Chieh-I Chen, Krishnansu S. Tewari
Publikováno v:
Scientia
Chemotherapy; Quality of life; Symptoms Quimioterapia; Calidad de vida; Síntomas Quimioteràpia; Qualitat de vida; Símptomes Background In a phase III, randomised, active-controlled study (EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9; R2810-ONC-1676; NCT0
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7902ba76c90b86f4278bb8b41600848
https://doi.org/10.1016/j.ejca.2022.03.016
https://doi.org/10.1016/j.ejca.2022.03.016
Autor:
Josep Tabernero, Paulo M. Hoff, Lin Shen, Atsushi Ohtsu, Manish A. Shah, Asna Siddiqui, Sarah Heeson, Astrid Kiermaier, Harrison Macharia, Eleonora Restuccia, Yoon-Koo Kang
Publikováno v:
Scientia
Background Dual-targeted anti-HER2 therapy significantly improves outcomes in HER2-positive breast cancer and could be beneficial in other HER2-positive cancers. JACOB’s end-of study analyses aimed to evaluate the long-term efficacy and safety of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b405a466248cd7cec2dc6bcf2cdfd68b
https://doi.org/10.1007/s10120-022-01335-4
https://doi.org/10.1007/s10120-022-01335-4
Autor:
Lionel Adès, Larisa Girshova, Vadim A. Doronin, María Díez-Campelo, David Valcárcel, Suman Kambhampati, Nora-Athina Viniou, Dariusz Woszczyk, Raquel De Paz Arias, Argiris Symeonidis, Achilles Anagnostopoulos, Eduardo Ciliao Munhoz, Uwe Platzbecker, Valeria Santini, Robert J. Fram, Ying Yuan, Sharon Friedlander, Douglas V. Faller, Mikkael A. Sekeres
Publikováno v:
Scientia
Pevonedistat; Chronic myelomonocytic leukemia Pevonedistat; Leucemia mielomonocítica crónica Pevonedistat; Leucèmia mielomonocítica crònica PANTHER is a global, randomized phase 3 trial of pevonedistat+azacitidine (n = 227) vs azacitidine monoth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8838e72608b49d5e2a82c322c09cf86
https://doi.org/10.1182/bloodadvances.2022007334
https://doi.org/10.1182/bloodadvances.2022007334
Autor:
Mariano Provencio, Roberto Serna-Blasco, Ernest Nadal, Amelia Insa, M. Rosario García-Campelo, Joaquín Casal Rubio, Manuel Dómine, Margarita Majem, Delvys Rodríguez-Abreu, Alex Martínez-Martí, Javier De Castro Carpeño, Manuel Cobo, Guillermo López Vivanco, Edel Del Barco, Reyes Bernabé Caro, Nuria Viñolas, Isidoro Barneto Aranda, Santiago Viteri, Eva Pereira, Ana Royuela, Virginia Calvo, Javier Martín-López, Francisco García-García, Marta Casarrubios, Fernando Franco, Estela Sánchez-Herrero, Bartomeu Massuti, Alberto Cruz-Bermúdez, Atocha Romero
Publikováno v:
JOURNAL OF CLINICAL ONCOLOGY
r-CIPF. Repositorio Institucional Producción Científica del Centro de Investigación Principe Felipe (CIPF)
Universitat Rovira i virgili (URV)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Scientia
r-CIPF. Repositorio Institucional Producción Científica del Centro de Investigación Principe Felipe (CIPF)
Universitat Rovira i virgili (URV)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Scientia
PURPOSE Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in resectable non–small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials.gov identifier: NCT03081689 ). The 3-year overall survival (OS) and circulating tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ea7330b9d5f399beeb1fe0adeeb286f
https://doi.org/10.1200/jco.21.02660
https://doi.org/10.1200/jco.21.02660
Autor:
Florent Guérin, Hélène Martelli, Timothy Rogers, Ilaria Zanetti, Sheila Terwisscha van Scheltinga, Federica De Corti, Gabriella Guillen Burrieza, Véronique Minard‐Colin, Daniel Orbach, Max M. van Noesel, Marie Karanian, Raquel Dávila Fajardo, Johannes H. M. Merks, Andrea Ferrari, Gianni Bisogno
Publikováno v:
Scientia
Liver; Pediatrics; Sarcoma Fetge; Pediatria; Sarcoma Hígado; Pediatría; Sarcoma Background To assess the outcomes of pediatric patients with undifferentiated embryonal sarcoma of the liver (UESL) and treatment including at least surgery and systemi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ebf7cd371b3cafacdb4a6d67acf9315
https://hdl.handle.net/11351/9836
https://hdl.handle.net/11351/9836
Autor:
Stefania Napolitano, Melanie Woods, Hey Min Lee, Vincenzo De Falco, Giulia Martini, Carminia Maria Della Corte, Erika Martinelli, Vincenzo Famiglietti, Davide Ciardiello, Amanda Anderson, Natalie Wall Fowlkes, Oscar Eduardo Villareal, Alexey Sorokin, Preeti Kanikarla, Olu Coker, Van Morris, Lucia Altucci, Josep Tabernero, Teresa Troiani, Fortunato Ciardiello, Scott Kopetz
Publikováno v:
Scientia
Purpose: Encorafenib + cetuximab (E+C) is an effective therapeutic option in chemorefractory BRAFV600E metastatic colorectal cancer (mCRC). However, there is a need to improve the efficacy of this molecular-targeted therapy and evaluate regimens suit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::206f53de24b61dea932f3c6f45b9c5eb
https://hdl.handle.net/11351/9975
https://hdl.handle.net/11351/9975
Autor:
Mattea Reinisch, Simona Bruzas, Oleg Gluz, Beyhan Ataseven, Peter Schmid, Javier Cortés, Jens‐Uwe Blohmer, Satyendra Shenoy, Mark H. Dyson, Christine Dittmer‐Grabowski, Ouafaa Chiari, Hakima Harrach, Daniel Gebauer, Alexander Traut, Sherko Kuemmel
Publikováno v:
Scientia
Adjuvant chemotherapy; Early breast cancer; Lymph node-positive Quimioterapia adyuvante; Cáncer de mama temprano; Ganglio linfático positivo Quimioteràpia adjuvant; Càncer de mama precoç; Gangli limfàtic positiu The utility of multigene express
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c681926851bcc6c69d8713c7a7499fe7
https://hdl.handle.net/11351/9976
https://hdl.handle.net/11351/9976
Autor:
Yelena Y Janjigian, Eric Van Cutsem, Kei Muro, Zev Wainberg, Salah-Eddin Al-Batran, Woo Jin Hyung, Daniela Molena, Michelle Marcovitz, Dario Ruscica, Scott H Robbins, Alejandra Negro, Josep Tabernero
Publikováno v:
Scientia
Standard-of-care for resectable gastric/gastroesophageal junction cancer includes surgery and neoadjuvant-adjuvant 5-fluorouracil-leucovorin-oxaliplatin-docetaxel (FLOT) chemotherapy. Early-phase clinical studies support further clinical development
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0492009e5e8d9dc41f76ff1f1af22e93
https://doi.org/10.2217/fon-2022-0093
https://doi.org/10.2217/fon-2022-0093